MedCity News June 14, 2024
Bristol Myers Squibb drug Augtyro now has a tumor-agnostic approval permitting the drug to be used to treat all solid tumors positive for NTRK gene fusions. Augtyro came from BMS’s $4.1 billion acquisition of Turning Point Therapeutics.
A Bristol Myers Squibb drug initially approved for treating lung cancer now has an additional FDA approval that expands its use to all solid tumors — as long as those tumors have a particular genetic signature.
The late Thursday regulatory decision for repotrectinib, brand name Augtyro, covers the treatment of adults as well as adolescents age 12 and older whose solid tumors have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion. These tumors must be advanced to the point where surgically removing them...
Today's Sponsors
Today's Sponsor